A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Esophagus | Larynx | Lip, Oral Cavity and Pharynx | Thyroid | Phase I
What is the purpose of this trial?
This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Ages18 years and older
- Trial withCue Biopharma, Inc.
- Start Date05/10/2022
- End Date07/31/2022
- Last Updated07/12/2022
- Study HIC#2000026098